Atea reports $136M FY2023 net loss; HCV Phase 2 confirms 98% SVR4; COVID-19 Phase 3 enrollment >1,400

Atea Pharmaceuticals, Inc.

2023-FY EPS reported -$1.63

Q4 net loss $39.2M ($0.47 diluted EPS) vs $34.4M loss in Q4 2022; FY net loss $136.0M ($1.63) vs $115.9M.
Cash & marketable securities $578.1M at Dec 31, 2023, down from $646.7M at Dec 31, 2022.
HCV Phase 2 lead-in final results: 98% SVR4 (58/59 patients); enrollment reinitiated for up to 220 patients, including cirrhotics.
COVID-19 Phase 3 SUNRISE-3: >1,400 patients enrolled in monotherapy cohort; interim analyses expected March 2024 and Q2 2024.
Topline results for SUNRISE-3 and HCV Phase 2 SVR12 both anticipated in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-050724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.